Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 2003 Feb;111(2):155–159. doi: 10.1289/ehp.5457

Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwan.

Shu-Li Wang 1, Jeng-Min Chiou 1, Chien-Jen Chen 1, Chin-Hsiao Tseng 1, Wei-Ling Chou 1, Cheng-Chung Wang 1, Trong-Neng Wu 1, Louis W Chang 1
PMCID: PMC1241343  PMID: 12573898

Abstract

There is evidence indicating that ingestion of arsenic may predispose the development of diabetes mellitus in arsenic-endemic areas in Taiwan. However, the prevalence of diabetes and related vascular diseases in the entire southwestern arseniasis-endemic and nonendemic areas remains to be elucidated. We used the National Health Insurance Database for 1999-2000 to derive the prevalence of non-insulin-dependent diabetes and related vascular diseases by age and sex among residents in southwestern arseniasis-endemic and nonendemic areas in Taiwan. The study included 66,667 residents living in endemic areas and 639,667 in nonendemic areas, all greater than or equal to 25 years of age. The status of diabetes and vascular diseases was ascertained through disease diagnosis and treatment prescription included in the reimbursement claims of clinics and hospitals. The prevalence of non-insulin-dependent diabetes, age- and gender-adjusted to the general population in Taiwan, was 7.5% (95% confidence interval, 7.4-7.7%) in the arseniasis-endemic areas and 3.5% (3.5-3.6%) in the nonendemic areas. Among both diabetics and nondiabetics, higher prevalence of microvascular and macrovascular diseases was observed in arseniasis-endemic than in the nonendemic areas. Age- and gender-adjusted prevalence of microvascular disease in endemic and nonendemic areas was 20.0% and 6.0%, respectively, for diabetics, and 8.6% and 1.0%, respectively, for nondiabetics. The corresponding prevalence of macrovascular disease was 25.3% and 13.7% for diabetics, and 12.3% and 5.5% for nondiabetics. Arsenic has been suggested to increase the risk of non-insulin-dependent diabetes mellitus and its related micro- and macrovascular diseases.

Full Text

The Full Text of this article is available as a PDF (143.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brouwer O. F., Onkenhout W., Edelbroek P. M., de Kom J. F., de Wolff F. A., Peters A. C. Increased neurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin Neurol Neurosurg. 1992;94(4):307–310. doi: 10.1016/0303-8467(92)90179-7. [DOI] [PubMed] [Google Scholar]
  2. Chang W. C., Chen S. H., Wu H. L., Shi G. Y., Murota S., Morita I. Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Toxicology. 1991;69(1):101–110. doi: 10.1016/0300-483x(91)90157-v. [DOI] [PubMed] [Google Scholar]
  3. Chen C. J., Chiou H. Y., Chiang M. H., Lin L. J., Tai T. Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol. 1996 Apr;16(4):504–510. doi: 10.1161/01.atv.16.4.504. [DOI] [PubMed] [Google Scholar]
  4. Chen C. J., Hsueh Y. M., Lai M. S., Shyu M. P., Chen S. Y., Wu M. M., Kuo T. L., Tai T. Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension. 1995 Jan;25(1):53–60. [PubMed] [Google Scholar]
  5. Chen C. J., Kuo T. L., Wu M. M. Arsenic and cancers. Lancet. 1988 Feb 20;1(8582):414–415. doi: 10.1016/s0140-6736(88)91207-x. [DOI] [PubMed] [Google Scholar]
  6. Chen C. J., Wu M. M., Lee S. S., Wang J. D., Cheng S. H., Wu H. Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis. 1988 Sep-Oct;8(5):452–460. doi: 10.1161/01.atv.8.5.452. [DOI] [PubMed] [Google Scholar]
  7. Cheng S. H., Chiang T. L. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA. 1997 Jul 9;278(2):89–93. doi: 10.1001/jama.278.2.89. [DOI] [PubMed] [Google Scholar]
  8. Chiang T. L. Taiwan's 1995 health care reform. Health Policy. 1997 Mar;39(3):225–239. doi: 10.1016/s0168-8510(96)00877-9. [DOI] [PubMed] [Google Scholar]
  9. Chiou H. Y., Hsueh Y. M., Hsieh L. L., Hsu L. I., Hsu Y. H., Hsieh F. I., Wei M. L., Chen H. C., Yang H. T., Leu L. C. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res. 1997 Jun;386(3):197–207. doi: 10.1016/s1383-5742(97)00005-7. [DOI] [PubMed] [Google Scholar]
  10. Chiou H. Y., Huang W. I., Su C. L., Chang S. F., Hsu Y. H., Chen C. J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997 Sep;28(9):1717–1723. doi: 10.1161/01.str.28.9.1717. [DOI] [PubMed] [Google Scholar]
  11. Curcio F., Ceriello A. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev Biol. 1992 Nov-Dec;28A(11-12):787–790. doi: 10.1007/BF02631069. [DOI] [PubMed] [Google Scholar]
  12. Del Razo L. M., Quintanilla-Vega B., Brambila-Colombres E., Calderón-Aranda E. S., Manno M., Albores A. Stress proteins induced by arsenic. Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132–148. doi: 10.1006/taap.2001.9291. [DOI] [PubMed] [Google Scholar]
  13. Fladeby C., Serck-Hanssen G. Stress-induced glucose uptake in bovine chromaffin cells: a comparison of the effect of arsenite and anisomycin. Biochim Biophys Acta. 1999 Dec 9;1452(3):313–321. doi: 10.1016/s0167-4889(99)00145-7. [DOI] [PubMed] [Google Scholar]
  14. Frost S. C., Lane M. D. Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem. 1985 Mar 10;260(5):2646–2652. [PubMed] [Google Scholar]
  15. Gopaul N. K., Manraj M. D., Hébé A., Lee Kwai Yan S., Johnston A., Carrier M. J., Anggård E. E. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia. 2001 Jun;44(6):706–712. doi: 10.1007/s001250051679. [DOI] [PubMed] [Google Scholar]
  16. Harris M. I., Hadden W. C., Knowler W. C., Bennett P. H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes. 1987 Apr;36(4):523–534. doi: 10.2337/diab.36.4.523. [DOI] [PubMed] [Google Scholar]
  17. Henriksen E. J., Holloszy J. O. Effects of phenylarsine oxide on stimulation of glucose transport in rat skeletal muscle. Am J Physiol. 1990 Apr;258(4 Pt 1):C648–C653. doi: 10.1152/ajpcell.1990.258.4.C648. [DOI] [PubMed] [Google Scholar]
  18. Hughes M. F., Thompson D. J. Subchronic dispositional and toxicological effects of arsenate administered in drinking water to mice. J Toxicol Environ Health. 1996 Oct 11;49(2):177–196. doi: 10.1080/009841096160916. [DOI] [PubMed] [Google Scholar]
  19. Jhun B. H., Hah J. S., Jung C. Y. Phenylarsine oxide causes an insulin-dependent, GLUT4-specific degradation in rat adipocytes. J Biol Chem. 1991 Nov 25;266(33):22260–22265. [PubMed] [Google Scholar]
  20. Kuzuya T. Prevalence of diabetes mellitus in Japan compiled from literature. Diabetes Res Clin Pract. 1994 Oct;24 (Suppl):S15–S21. doi: 10.1016/0168-8227(94)90222-4. [DOI] [PubMed] [Google Scholar]
  21. Lai M. S., Hsueh Y. M., Chen C. J., Shyu M. P., Chen S. Y., Kuo T. L., Wu M. M., Tai T. Y. Ingested inorganic arsenic and prevalence of diabetes mellitus. Am J Epidemiol. 1994 Mar 1;139(5):484–492. doi: 10.1093/oxfordjournals.aje.a117031. [DOI] [PubMed] [Google Scholar]
  22. Liebl B., Mückter H., Doklea E., Fichtl B., Forth W. Influence of 2,3-dimercaptopropanol and other sulfur compounds on oxophenylarsine-mediated inhibition of glucose uptake in MDCK cells. Analyst. 1995 Mar;120(3):771–774. doi: 10.1039/an9952000771. [DOI] [PubMed] [Google Scholar]
  23. Longnecker M. P., Daniels J. L. Environmental contaminants as etiologic factors for diabetes. Environ Health Perspect. 2001 Dec;109 (Suppl 6):871–876. doi: 10.1289/ehp.01109s6871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diabetes Metab Rev. 1992 Jul;8(2):85–103. doi: 10.1002/dmr.5610080202. [DOI] [PubMed] [Google Scholar]
  25. Lynn S., Gurr J. R., Lai H. T., Jan K. Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res. 2000 Mar 17;86(5):514–519. doi: 10.1161/01.res.86.5.514. [DOI] [PubMed] [Google Scholar]
  26. Mahajan S. K., Aggarwal H. K., Wig N., Maitra S., Chugh S. N. Arsenic induced neuropathy. J Assoc Physicians India. 1992 Apr;40(4):268–269. [PubMed] [Google Scholar]
  27. Mitchell R. D., Ayala-Fierro F., Carter D. E. Systemic indicators of inorganic arsenic toxicity in four animal species. J Toxicol Environ Health A. 2000 Jan 28;59(2):119–134. doi: 10.1080/009841000157014. [DOI] [PubMed] [Google Scholar]
  28. Morales K. H., Ryan L., Kuo T. L., Wu M. M., Chen C. J. Risk of internal cancers from arsenic in drinking water. Environ Health Perspect. 2000 Jul;108(7):655–661. doi: 10.1289/ehp.00108655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rahman M., Axelson O. Diabetes mellitus and arsenic exposure: a second look at case-control data from a Swedish copper smelter. Occup Environ Med. 1995 Nov;52(11):773–774. doi: 10.1136/oem.52.11.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rahman M., Tondel M., Ahmad S. A., Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol. 1998 Jul 15;148(2):198–203. doi: 10.1093/oxfordjournals.aje.a009624. [DOI] [PubMed] [Google Scholar]
  31. Rahman M., Wingren G., Axelson O. Diabetes mellitus among Swedish art glass workers--an effect of arsenic exposure? Scand J Work Environ Health. 1996 Apr;22(2):146–149. doi: 10.5271/sjweh.123. [DOI] [PubMed] [Google Scholar]
  32. Singh R. B., Bajaj S., Niaz M. A., Rastogi S. S., Moshiri M. Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol. 1998 Sep 1;66(1):65–72. doi: 10.1016/s0167-5273(98)00141-7. [DOI] [PubMed] [Google Scholar]
  33. Suzuki K. T., Tomita T., Ogra Y., Ohmichi M. Glutathione-conjugated arsenics in the potential hepato-enteric circulation in rats. Chem Res Toxicol. 2001 Dec;14(12):1604–1611. doi: 10.1021/tx0155496. [DOI] [PubMed] [Google Scholar]
  34. Tsai S. M., Wang T. N., Ko Y. C. Cancer mortality trends in a blackfoot disease endemic community of Taiwan following water source replacement. J Toxicol Environ Health A. 1998 Nov 27;55(6):389–404. doi: 10.1080/009841098158322. [DOI] [PubMed] [Google Scholar]
  35. Tseng C. H., Chong C. K., Chen C. J., Tai T. Y. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis. 1996 Feb;120(1-2):125–133. doi: 10.1016/0021-9150(95)05693-9. [DOI] [PubMed] [Google Scholar]
  36. Tseng C. H., Tai T. Y., Chong C. K., Tseng C. P., Lai M. S., Lin B. J., Chiou H. Y., Hsueh Y. M., Hsu K. H., Chen C. J. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect. 2000 Sep;108(9):847–851. doi: 10.1289/ehp.00108847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wang Chih-Hao, Jeng Jiann-Shing, Yip Ping-Keung, Chen Chi-Ling, Hsu Lin-I, Hsueh Yu-Mei, Chiou Hung-Yi, Wu Meei-Mann, Chen Chien-Jen. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002 Apr 16;105(15):1804–1809. doi: 10.1161/01.cir.0000015862.64816.b2. [DOI] [PubMed] [Google Scholar]
  38. Wang S. L., Pan W. H., Hwu C. M., Ho L. T., Lo C. H., Lin S. L., Jong Y. S. Incidence of NIDDM and the effects of gender, obesity and hyperinsulinaemia in Taiwan. Diabetologia. 1997 Dec;40(12):1431–1438. doi: 10.1007/s001250050846. [DOI] [PubMed] [Google Scholar]
  39. Wu M. M., Chiou H. Y., Wang T. W., Hsueh Y. M., Wang I. H., Chen C. J., Lee T. C. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect. 2001 Oct;109(10):1011–1017. doi: 10.1289/ehp.011091011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wu M. M., Kuo T. L., Hwang Y. H., Chen C. J. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989 Dec;130(6):1123–1132. doi: 10.1093/oxfordjournals.aje.a115439. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES